MA33930B1 - Nouveaux anticorps antagonistes contre gpvi et leurs fragments fab et utilisations de ceux-ci - Google Patents

Nouveaux anticorps antagonistes contre gpvi et leurs fragments fab et utilisations de ceux-ci

Info

Publication number
MA33930B1
MA33930B1 MA35073A MA35073A MA33930B1 MA 33930 B1 MA33930 B1 MA 33930B1 MA 35073 A MA35073 A MA 35073A MA 35073 A MA35073 A MA 35073A MA 33930 B1 MA33930 B1 MA 33930B1
Authority
MA
Morocco
Prior art keywords
fab
relates
antibodies
fragments
gpvi
Prior art date
Application number
MA35073A
Other languages
Arabic (ar)
English (en)
Inventor
Nicolas Baurin
Francis Blanche
Béatrice Cameron
Carsten Corvey
Tarik Dabdoubi
Christian Engel
Peter Florian
Ingo Focken
Katja Kroll
Jochen Kruip
Christian Lange
Thomas Langer
Martin Lorenz
Vincent Mikol
Ercole Rao
Peter Wonerow
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP09306283A external-priority patent/EP2336188A1/fr
Priority claimed from EP10305660A external-priority patent/EP2397495A1/fr
Priority claimed from EP10305721A external-priority patent/EP2402371A1/fr
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of MA33930B1 publication Critical patent/MA33930B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1075—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of amino acids or peptide residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Vascular Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La présente invention concerne de nouveaux anticorps qui se lient de manière spécifique à la protéine membranaire plaquettaire humaine, Glycoprotéine VI, et leurs fragments ou dérivés monovalents. Les anticorps de l'invention sont des anticorps issus du clone d'hybridome 390 et des anticorps fragments de ceux-ci capables d'induire un phénotype de déplétion en GPVI. Ces anticorps et fragments Fab sont capables de bloquer la liaison du collagène et ainsi d'empêcher l'activation des plaquettes par le collagène. L'invention concerne également des clones d'hybridome et des plasmides d'expression pour la production des anticorps et des fragments Fab décrits. La présente invention concerne en outre les utilisations de fragments d'anticorps monovalents pour fabriquer des agents de recherche, de diagnostic et d'immunothérapie pour le traitement de la thrombose et d'autres maladies vasculaires. L'invention concerne également un Fab portant une molécule à l'extrémité C-terminale, ainsi qu'un procédé de prévention de la reconnaissance de Fab par des anticorps en utilisant un tel Fab modifié. L'invention concerne un procédé de prévention de l'activation des plaquettes lorsqu'un Fab anti-GP VI est utilisé.
MA35073A 2009-12-18 2010-12-17 Nouveaux anticorps antagonistes contre gpvi et leurs fragments fab et utilisations de ceux-ci MA33930B1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP09306283A EP2336188A1 (fr) 2009-12-18 2009-12-18 Nouveaux anticorps antagonistes et leurs fragments Fab contre le GPVI et leurs utilisations
EP10305660A EP2397495A1 (fr) 2010-06-21 2010-06-21 Nouveaux anticorps antagonistes et leurs fragments Fab contre le GPVI et leurs utilisations
EP10305721A EP2402371A1 (fr) 2010-07-01 2010-07-01 Nouveaux anticorps antagonistes et leurs fragments Fab contre le GPVI et leurs utilisations
PCT/IB2010/055917 WO2011073954A2 (fr) 2009-12-18 2010-12-17 Nouveaux anticorps antagonistes et leurs fragments fab dirigés contre gpvi, et utilisations de ceux-ci

Publications (1)

Publication Number Publication Date
MA33930B1 true MA33930B1 (fr) 2013-01-02

Family

ID=44060924

Family Applications (1)

Application Number Title Priority Date Filing Date
MA35073A MA33930B1 (fr) 2009-12-18 2010-12-17 Nouveaux anticorps antagonistes contre gpvi et leurs fragments fab et utilisations de ceux-ci

Country Status (30)

Country Link
US (2) US8852593B2 (fr)
EP (2) EP2933269A1 (fr)
JP (1) JP5843783B2 (fr)
KR (1) KR20120102125A (fr)
CN (1) CN102725309B (fr)
AR (1) AR079645A1 (fr)
AU (1) AU2010331807B2 (fr)
BR (1) BR112012014975A2 (fr)
CA (1) CA2784498A1 (fr)
CL (1) CL2012001650A1 (fr)
CY (1) CY1118389T1 (fr)
DK (1) DK2513147T3 (fr)
EA (1) EA201290525A1 (fr)
ES (1) ES2596254T3 (fr)
HK (1) HK1216537A1 (fr)
HR (1) HRP20161298T1 (fr)
HU (1) HUE029824T2 (fr)
IL (1) IL220447A0 (fr)
LT (1) LT2513147T (fr)
MA (1) MA33930B1 (fr)
MX (2) MX347613B (fr)
PH (1) PH12012501219A1 (fr)
PL (1) PL2513147T3 (fr)
PT (1) PT2513147T (fr)
SG (2) SG10201405259PA (fr)
SI (1) SI2513147T1 (fr)
TW (1) TW201132759A (fr)
UY (1) UY33115A (fr)
WO (1) WO2011073954A2 (fr)
ZA (1) ZA201204421B (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2860453T3 (es) 2009-10-30 2021-10-05 Novartis Ag Bibliotecas universales del dominio de unión del lado inferior de la fibronectina de tipo III
TW201132759A (en) * 2009-12-18 2011-10-01 Sanofi Aventis Novel antagonist antibodies and their FaB fragments against GPVI and uses thereof
EP2621953B1 (fr) 2010-09-30 2017-04-05 Ablynx N.V. Matières biologiques associées à c-met
US11644471B2 (en) 2010-09-30 2023-05-09 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
CA2858350A1 (fr) 2011-01-14 2013-07-19 The Regents Of The University Of California Anticorps therapeutiques contre la proteine ror-1 et leurs methodes d'utilisation
HUE031828T2 (en) 2011-06-23 2017-08-28 Ablynx Nv Procedures for Predicting, Detecting, and Reducing Aspiration Protein Interference in Assays Containing Immunoglobulin Variable Single Domain
EP3466972B1 (fr) 2011-06-23 2026-03-04 Ablynx NV Protéines de liaison de l'albumine sérique
EP4350345A3 (fr) * 2011-06-23 2024-07-24 Ablynx N.V. Techniques de prediction, de detection et de reduction d'interferences de proteines specifiques dans des dosages impliquant des domaines variables simples d'immunoglobulines
EP2944654A1 (fr) * 2011-06-23 2015-11-18 Ablynx N.V. Techniques de prédiction, de détection et de réduction d'une interférence de protéines spécifiques dans des analyses impliquant des domaines variables simples d'immunoglobulines
PE20141522A1 (es) * 2011-08-17 2014-11-17 Glaxo Group Ltd Proteinas y peptidos modificados
US9346884B2 (en) 2011-09-30 2016-05-24 Ablynx N.V. Biological materials related to c-Met
US9328174B2 (en) 2012-05-09 2016-05-03 Novartis Ag Chemokine receptor binding polypeptides
US20140161796A1 (en) * 2012-09-13 2014-06-12 Andreas Loew Single chain proteins with c-terminal modifications
CN103396492A (zh) * 2013-08-06 2013-11-20 安徽新标志科技有限公司 抗人血小板胶原蛋白受体的人源性单克隆抗体片段及其应用
SMT202200317T1 (it) * 2015-08-05 2022-09-14 Inst Nat Sante Rech Med Anticorpi anti-gpvi umana innovativi e relativi usi
EP3538552B1 (fr) 2016-11-14 2023-09-13 MorphoSys AG Molécules fab ayant une région charnière de rongeur et une région ch1 de non-rongeur
JP7360945B2 (ja) 2017-02-03 2023-10-13 アクティコー バイオテック 抗ヒトｇｐｖｉ抗体を用いた血小板凝集の阻害
CA3097253A1 (fr) * 2018-05-16 2019-11-21 Morphosys Ag Anticorps ciblant la glycoproteine vi
GB202020602D0 (en) * 2020-12-24 2021-02-10 Univ Birmingham Nanobody
CN118043349B (zh) * 2021-06-11 2024-11-15 丰华生物有限公司 一种人源化抗人GPVI单克隆抗体Fab片段及其应用
WO2023133470A2 (fr) * 2022-01-07 2023-07-13 BioLegend, Inc. Anticorps se liant à tmprss2 et leurs fragments de liaison à l'antigène
CN115991780B (zh) * 2022-12-29 2025-06-10 盖普思药业(重庆)有限公司 一种抗人血小板胶原蛋白受体gp-vi抗体或其抗原结合片段及其应用
EP4431526A1 (fr) 2023-03-16 2024-09-18 Emfret Analytics GmbH & Co. KG Anticorps anti-gpvi et fragments fonctionnels de ceux-ci

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6498237B2 (en) 1989-08-07 2002-12-24 Peptech Limited Tumor necrosis factor antibodies
US5919452A (en) * 1991-03-18 1999-07-06 New York University Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies
GB9109478D0 (en) * 1991-05-02 1991-06-26 Therapeutic Antibodies Inc Antivenoms
US7062219B2 (en) * 1997-01-31 2006-06-13 Odyssey Thera Inc. Protein fragment complementation assays for high-throughput and high-content screening
US7291714B1 (en) * 1999-06-30 2007-11-06 Millennium Pharmaceuticals, Inc. Glycoprotein VI and uses thereof
US20040001826A1 (en) * 1999-06-30 2004-01-01 Millennium Pharmaceuticals, Inc. Glycoprotein VI and uses thereof
WO2001016321A1 (fr) * 1999-09-01 2001-03-08 Otsuka Pharmaceutical Co., Ltd. Adn et sequences proteiniques de glycoproteine vi (gpvi) de membranes plaquettaires et utilisations de ceux-ci
AU1446801A (en) * 1999-10-29 2001-05-14 Rutgers, The State University Of New Jersey Renilla reniformis green fluorescent protein
AU2002211835A1 (en) * 2000-09-29 2002-04-08 Clinomics Laboratories, Inc. Oncology tissue microarrays
EP1224942A1 (fr) * 2001-01-23 2002-07-24 Bernhard Dr. Nieswandt Utilisation de JAQ1 (anticorps monoclonal anti-GPVI) en tant que médicament actif pour la protection contre les maladies thrombotiques
GB0130543D0 (en) * 2001-12-20 2002-02-06 Univ Cambridge Tech Human antibodies and their use
GB0511590D0 (en) 2005-06-07 2005-07-13 Procorde Gmbh Anti-thrombotic agents
EP1538165A1 (fr) * 2003-12-03 2005-06-08 Procorde GmbH Inhibiteurs de la glycoprotéine VI construits à partir de l'anticorps monoclonal hgp 5c4
EP1369128A1 (fr) * 2002-06-07 2003-12-10 Procorde GmbH Inhibiteurs de glycoprotéine VI et leur utilisation thérapeutique
CN100558895C (zh) * 2003-07-18 2009-11-11 持田制药株式会社 抗血小板膜糖蛋白vi单克隆抗体
WO2005090407A1 (fr) * 2004-03-19 2005-09-29 Imclone Systems Incorporated Anticorps du recepteur du facteur de croissance anti-epidermique humain
AU2005243193B2 (en) * 2004-04-29 2011-01-27 Otsuka Pharmaceutical Co., Ltd. Antibodies specific for glycoprotein VI and methods of producing these antibodies
EP1824979A2 (fr) * 2004-12-10 2007-08-29 Trigen GmbH Procedes, produits et utilisations relatifs a des plaquettes et/ou la vasculature
GB0502358D0 (en) * 2005-02-04 2005-03-16 Novartis Ag Organic compounds
WO2006117910A1 (fr) * 2005-04-28 2006-11-09 Mochida Pharmaceutical Co., Ltd. Anticorps monoclonal contre la glycoproteine vi de la membrane de la plaquette
CA2606450A1 (fr) 2005-04-28 2006-11-09 Mochida Pharmaceutical Co., Ltd. Anticorps monoclonal anti-glycoproteine vi de membrane plaquettaire
JP5224707B2 (ja) * 2005-04-28 2013-07-03 持田製薬株式会社 抗血小板膜糖蛋白質ｖｉモノクローナル抗体
JPWO2007091719A1 (ja) * 2006-02-07 2009-07-02 持田製薬株式会社 抗ｇｐｖｉ抗体の併用療法及び新規医薬用途
JPWO2007116779A1 (ja) 2006-03-31 2009-08-20 持田製薬株式会社 新規血小板活性化マーカー及びその測定方法
EP1916259A1 (fr) * 2006-10-26 2008-04-30 Institut National De La Sante Et De La Recherche Medicale (Inserm) Fragment SCFV anti-gycoprotéine VI pour le traitement de la thrombose
PE20090993A1 (es) 2007-08-29 2009-07-08 Sanofi Aventis Anticuerpos anti-cxcr5 humanizados y derivados de los mismos
RU2010121878A (ru) * 2007-10-31 2011-12-10 Оцука Фармасьютикал Ко., Лтд. (Jp) Применения ингибитора гликопротеина vi (gpvi)
AU2009308707A1 (en) * 2008-10-31 2010-05-06 Biogen Idec Ma Inc. LIGHT targeting molecules and uses thereof
TW201132759A (en) * 2009-12-18 2011-10-01 Sanofi Aventis Novel antagonist antibodies and their FaB fragments against GPVI and uses thereof

Also Published As

Publication number Publication date
CA2784498A1 (fr) 2011-06-23
HK1216537A1 (en) 2016-11-18
BR112012014975A2 (pt) 2019-09-24
DK2513147T3 (en) 2016-10-24
EP2513147A2 (fr) 2012-10-24
CY1118389T1 (el) 2017-06-28
CN102725309B (zh) 2016-01-06
SI2513147T1 (sl) 2016-11-30
US20150098939A1 (en) 2015-04-09
KR20120102125A (ko) 2012-09-17
US20120244152A1 (en) 2012-09-27
US8852593B2 (en) 2014-10-07
PL2513147T3 (pl) 2017-08-31
AU2010331807B2 (en) 2016-08-04
MX2012007153A (es) 2012-07-03
US9441040B2 (en) 2016-09-13
JP2013514077A (ja) 2013-04-25
SG10201405259PA (en) 2014-10-30
EP2513147B1 (fr) 2016-07-20
EP2933269A1 (fr) 2015-10-21
WO2011073954A2 (fr) 2011-06-23
MX347613B (es) 2017-05-04
WO2011073954A3 (fr) 2012-03-08
CN102725309A (zh) 2012-10-10
CL2012001650A1 (es) 2012-12-14
EA201290525A1 (ru) 2013-01-30
TW201132759A (en) 2011-10-01
ZA201204421B (en) 2013-09-25
AR079645A1 (es) 2012-02-08
LT2513147T (lt) 2016-10-25
SG181707A1 (en) 2012-07-30
PH12012501219A1 (en) 2017-08-23
HUE029824T2 (en) 2017-04-28
UY33115A (es) 2011-07-29
PT2513147T (pt) 2016-10-11
JP5843783B2 (ja) 2016-01-13
AU2010331807A1 (en) 2012-07-12
HRP20161298T1 (hr) 2016-11-18
ES2596254T3 (es) 2017-01-05
IL220447A0 (en) 2012-08-30

Similar Documents

Publication Publication Date Title
EA201290525A1 (ru) Новые антитела-антагонисты, их fab-фрагменты против gpvi и способы их применения
PE20190920A1 (es) Anticuerpos modificados de union a fcrn humano y metodos de utilizacion
ZA202005259B (en) Anti-ctla4 antibodies and methods of making and using the same
UA109633C2 (uk) Антитіло людини проти тканинного фактора
PE20200152A1 (es) Receptores de union a antigeno mejorados
BR112018075737A2 (pt) anticorpo, composição, célula isolada, e, métodos para tratar câncer ou infecção em um paciente e para detectar expressão de pd-l1 em uma amostra.
EP2352523A4 (fr) Anticorps anti-cd19 améliorés
MX381183B (es) Proteínas de fusión de serpina-fc de inmunoglobulina de humano y método de purificación de las mismas.
WO2011119979A3 (fr) Anticorps anti-muc16 et leurs procédés d'utilisation
AR086579A1 (es) Proteinas de union a antigeno
MX2019002967A (es) Anticuerpos de union a cd3.
UA118332C2 (uk) Білок, що зв'язує антиген cd27l
CY1119410T1 (el) Βελτιστοποιημενα μονοκλωνικα αντισωματα εναντι του αναστολεα της οδου του ιστικου παραγοντα (tfpi)
PH12020550927A1 (en) Therapeutic enzyme fusion protein having novel structure and use thereof
PH12020551012A1 (en) Monoclonal antibodies and methods for using same
EA201991704A2 (ru) Моноклональные антитела против ингибитора пути тканевого фактора (tfpi)
BR112014010161A2 (pt) anticorpo monoclonal antiproteína de ligação ao dna tar de 43 kda (tdp-43) e seus método de preparação e uso no tratamento de proteinopatia tdp-43, bem como composições, polinucleotídeo, método in vitro e kit para diagnosticar proteinopatia tdp-43
TN2011000528A1 (en) Compositions and methods for antibodies targeting complement protein c3b
NZ603570A (en) Biological materials related to her3
CO2019006657A2 (es) Anticuerpos anti-cd73 y usos de los mismos
MX377570B (es) Proteínas de fusión ctla4 para el tratamiento de la diabetes.
BR112022023697A2 (pt) Métodos e meios para a produção de moléculas semelhantes a ig
EA201690114A1 (ru) КОНЪЮГАТ Fc ИММУНОГЛОБУЛИНА, СОХРАНЯЮЩИЙ СПОСОБНОСТЬ СВЯЗЫВАНИЯ С FcRn
ZA202110285B (en) Antibodies and methods of use
HK1198427A1 (en) Human notch1 decoys